贵州益佰制药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量（含本次质押和解除质押）为 138,912,050 股，占其持股 数量的 74.90%，占公司总股本的 17.54%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量（含本 次质押和解除质押）为 138,912,050 股，占窦啟玲女士及其一致行动人窦雅琪女 士合计所持公司股份的 74.80%，占公司总股本的 17.54%。 近日，公司接到控股股东窦啟玲女士的通知，获悉其将所持有的公司部分股 份办理了股票质押及解除质押业务，具体情况如下： 证券代码：600594 证券简称：益佰制药 公告编号：2025-003 本次解除质押的股份如后续用于其他质押业务，公司将及时进行信息披露。 三、股东累计质押股份情况 截至本 ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-002 贵州益佰制药股份有限公司 关于控股股东部分股份解除质押 及部分股份延期购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量（含本次解除质押和延期购回）为 133,602,712 股,占其 持股数量的 72.04%，占公司总股本的 16.87%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量（含本 次解除质押和延期购回）为 133,602,712 股，占窦啟玲女士及其一致行动人窦雅 琪女士合计所持公司股份的 71.94%，占公司总股本的 16.87%。 一、本次股份解除质押情况 近日，公司接到控股股东窦啟玲女士的通知，获悉其将所持有的公司部分股 份办理了解除质押手续，具体情况如下： 本次解除质押的股份如后续用于其他质押业务，公司将及时进行信息披 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -342 million and -285 million RMB, indicating a loss compared to the previous year[3]. - The projected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -348 million and -290 million RMB[4]. - In 2023, the total profit was 132.32 million RMB, with a net profit attributable to shareholders of the parent company of 103.40 million RMB[6]. - The earnings per share for 2023 was 0.131 RMB[6]. Reasons for Expected Loss - The main reason for the expected loss is the halt in production and sales of the main product, Aidi injection, leading to a revenue decline of approximately 480 million RMB[7]. - Additionally, the price reduction of products such as injection-grade lobaplatin and ginkgo biloba injection resulted in a revenue decrease of about 190 million RMB[7]. Performance Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[8]. - The company assures that there are no significant uncertainties affecting the accuracy of this performance forecast[8]. - Investors are advised to pay attention to investment risks as the forecast data is preliminary and subject to change upon the release of the audited annual report[9]. Announcement Details - The announcement was made by the board of directors on January 18, 2025[11].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量为 148,180,650 股，占其持股数量的 79.90%，占公司总 股本的 18.71%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量为 148,180,650 股，占窦啟玲女士及其一致行动人窦雅琪女士合计所持公司股份的 79.79%，占公司总股本的 18.71%。 证券代码：600594 证券简称：益佰制药 公告编号：2024-049 贵州益佰制药股份有限公司 股票质押式回购交易延期购回公告 截至本公告披露日，上述股东及其一致行动人累计质押股份情况如下： 注：以上数据因四舍五入原因导致数据在尾数上略有差异。 二、控股股东股份质押情况 1、窦啟玲女士未来半年内到期的累计股份质押数量为 148,180,650 股,占其 持股总数的 79.90%，占公司总股本的 18.7 ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-049 贵州益佰制药股份有限公司 一、本次股份质押延期购回情况 近日，公司接到控股股东窦啟玲女士的通知，获悉其将所持有的公司部分股 份办理了股票质押延期购回业务，具体情况如下： | 股 | 是否 | 本次延期购 | 是否 | 是否 | | | | | 占其所 | 占公司 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 东 | 为控 | | | | 初始交易 | 原购回交 | 延期后购 | 质权 | | | 融资 | | 名 | 股股 | 回股份数 | 为限 | 补充 | 日 | 易日 | 回日 | 人 | 持股份 | 总股本 | 资金 | | | | （股） | 售股 | 质押 | | | | | 比例 | 比例 | | | 称 | 东 | | | | | | | | | | 用途 | | 窦 | | 35,000,000 | | | 2022/11/7 | | | 海通 证券 | 18.87% | 4.42% | | | | | ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-048 贵州益佰制药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （三）公司本次回购股份总金额已达到回购方案下限，回购方案实际执行情 况与原披露的回购方案不存在差异，公司已按披露的方案完成回购。 贵州益佰制药股份有限公司（以下简称"公司"）于 2023 年 11 月 29 日召开 第八届董事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股份 预案的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股份，本次 回购股份拟用于实施员工持股计划或股权激励，拟回购股份资金总额不低于人民 币 2,000.00 万元（含）且不超过人民币 4,000.00 万元（含），回购股份价格不 超过人民币 8.65 元/股（含），回购股份期限为自公司董事会审议通过回购方案 之日起不超过 12 个月。经 2023 年年度权益分派除权除息后，公司股份回购价格 由不超过人民币 8.65 元/股（含）调整为不超过人民币 8.58 ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-047 贵州益佰制药股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 （一）会议召开时间：2024 年 11 月 28 日 星期四 15:00-16:00 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 28 日 星期四 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动方式 投资者可于 2024 年 11 月 21 日（星期四）至 11 月 27 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过贵州益佰制药股份 有限公司（以下简称"公司"）邮箱（600594@gz100.cn）进行提问。公司将在说 明会上对投资者普遍关注的问题进行回答。 公司已于 2024 年 10 月 26 日在上海证券交易所网站 （h ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-046 贵州益佰制药股份有限公司 股票质押式回购交易延期购回公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量为 148,180,650 股，占其持股数量的 79.90%，占公司总 股本的 18.71%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量为 148,180,650 股，占窦啟玲女士及其一致行动人窦雅琪女士合计所持公司股份的 79.79%，占公司总股本的 18.71%。 一、本次股份质押延期购回情况 近日，公司接到控股股东窦啟玲女士的通知，获悉其将所持有的公司部分股 份办理了股票质押延期购回业务，具体情况如下： | 股 | 是否 | | | | | | | | | | 质押 | | --- | --- | --- | --- | --- | - ...

证券代码：600594 证券简称：益佰制药 公告编号：2024-045 重要内容提示： | 回购方案首次披露日 | 2023/11/30 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2023 年 日至 2024 年 11 | 月 | 29 | 月 | 28 | 日 | 11 | | 预计回购金额 | 2,000 万元~4,000 万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 5,037,400 股 | | | | | | | | 累计已回购股数占总股本比例 | 0.64% | | | | | | | | 累计已回购金额 | 14,997,308 元 | | | | | | | | 实际回购价格区间 | 2.89 元/股至 3.06 元/股 | | | | | | | 一、 回购股 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥545,648,893.87, representing a decrease of 16.97% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥62,657,845.21, a decline of 249.31% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was -¥68,092,758.30, down 275.13% from the previous year[2]. - The net profit for the third quarter of 2024 was -174,241,819.86 CNY, compared to a net profit of 161,499,907.31 CNY in the same period of 2023, indicating a significant decline[18]. - The total profit margin for the third quarter of 2024 was significantly impacted, with a total profit of -173,766,399.26 CNY compared to a profit of 194,907,546.17 CNY in the same period of 2023[18]. - Total operating revenue for the first three quarters of 2024 was CNY 1,713,840,317.37, a decrease of 19.7% compared to CNY 2,136,834,252.04 in the same period of 2023[17]. - The company's net profit attributable to shareholders decreased significantly, with undistributed profits dropping to CNY 902,047,094.34 from CNY 1,123,465,581.46, a decline of 19.7%[15]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥4,167,157,491.04, a decrease of 9.36% compared to the end of the previous year[4]. - Total assets decreased to CNY 4,167,157,491.04 in Q3 2024 from CNY 4,597,253,863.18 in Q3 2023, a reduction of 9.3%[15]. - Total liabilities decreased to CNY 1,390,381,859.05 in Q3 2024 from CNY 1,578,998,904.30 in Q3 2023, a decline of 11.9%[15]. - The company reported a decrease in short-term borrowings to CNY 290,825,916.68 from CNY 446,045,418.03, a reduction of 34.8%[15]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥2,648,055,698.32, a decrease of 8.20% from the previous year[4]. Cash Flow and Expenses - The cash flow from operating activities for the year-to-date was ¥199,803,322.61, down 41.77% compared to the previous year[4]. - The cash flow from operating activities for the third quarter of 2024 was 199,803,322.61 CNY, compared to 343,155,292.85 CNY in the same quarter of 2023, reflecting a decline of about 41.8%[22]. - The company incurred operating expenses of 1,867,618,947.16 CNY in the third quarter of 2024, compared to 2,002,763,789.31 CNY in the same quarter of 2023, showing a reduction in expenses[22]. - The cash flow from investing activities for the third quarter of 2024 was -56,385,904.48 CNY, compared to -102,439,355.09 CNY in the same quarter of 2023, indicating an improvement in cash outflow[22]. - The company raised 380,000,000.00 CNY through financing activities in the third quarter of 2024, down from 530,000,000.00 CNY in the same quarter of 2023[22]. Share Repurchase - The company plans to repurchase shares with a total amount between RMB 20 million and RMB 40 million, with a maximum repurchase price set at RMB 8.58 per share[12]. - As of September 30, 2024, the company has repurchased a total of 5,037,400 shares, accounting for 0.64% of the total share capital[12]. - The highest repurchase price recorded was RMB 3.06 per share, while the lowest was RMB 2.89 per share[12]. - The total amount paid for share repurchases reached RMB 14,997,308, excluding transaction fees[12]. - The company held a board meeting on November 29, 2023, to approve the share repurchase plan[12]. Current Assets - As of September 30, 2024, the total current assets decreased to RMB 1,732,617,097.29 from RMB 2,069,148,018.19 at the end of 2023, representing a decline of approximately 16.2%[13]. - Cash and cash equivalents amounted to RMB 619,878,982.72, down from RMB 699,468,723.75, indicating a decrease of about 11.4%[13]. - Accounts receivable increased to RMB 239,754,999.02 from RMB 227,055,742.82, reflecting an increase of approximately 5.9%[13]. - Inventory decreased to RMB 552,834,263.39 from RMB 586,650,795.70, showing a decline of about 5.8%[13]. - The cash and cash equivalents at the end of the third quarter of 2024 were 607,876,290.72 CNY, down from 683,933,062.18 CNY at the end of the third quarter of 2023, a decrease of approximately 11.1%[23]. Research and Development - Research and development expenses increased to CNY 79,177,945.47 in 2024 from CNY 73,852,804.23 in 2023, representing a growth of 7.1%[17]. Future Plans - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters[16].